Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Rhythm Biosciences Ltd. ( (AU:RHY) ) is now available.
Rhythm Biosciences has disclosed the cessation of 750,000 fully paid ordinary employee performance rights (ASX code: RHYAR), which lapsed after the conditions attached to those rights were not met or became incapable of being satisfied as of 13 January 2026. The lapse reduces the pool of potential future share issuances tied to employee incentives, modestly tightening the company’s prospective capital base and reflecting adjustments to its employee equity scheme without impacting existing shareholders’ current holdings.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Limited (ASX: RHY) is an Australia-listed biotechnology company focused on developing diagnostic technologies, particularly in the medical and life sciences sector. The company operates in the healthcare and biosciences industry, with its securities traded on the Australian Securities Exchange under the ticker RHY.
Average Trading Volume: 470,619
Technical Sentiment Signal: Buy
Current Market Cap: A$42.13M
Find detailed analytics on RHY stock on TipRanks’ Stock Analysis page.